Stocks›Healthcare›ALKS

ALKS

Alkermes plc.

NasdaqResearch view

$40.85+0.15%

Sep 25 close · 1D EOD · Databento

HealthcarePharmaceutical PreparationsMid-capSEC EDGAR FY 2025-12-31

What happened

Daily closes · dots are Wire stories

1 story has a settled receipt so far (1 on the Wire). The record starts speaking at three.

What’s next

Expected around late October, going by its own filing history. The company has not announced a date yet. Its matching report came Oct 28, 2025 and Oct 24, 2024, before the open.

Last report

Jul 28, 2026−4.23%

before the open

Last 4, next close

median 5.16% either way

up 1 of 4

Every report since 2023 →

DateEventSourceNext close

Aug 24Alkermes narcolepsy drug shows positive phase 2 trial resultsInvesting.comInvesting.com+0.70%
Jul 28Earnings release, before the open · 8-KSEC EDGARSEC EDGAR ↗−4.23%

Next close = the first close after the event against the close before it. Prior-session closes only; not a call, not advice.

Big days · last year

Daily closes · Databento EOD

28 big days: a close more than 4.06% from the one before, three times ALKS’s median day (1.35%). On 5 of 28, its largest peers moved the same way at least half as far. We show what we hold, never a cause.

Shaded: since our stories began, Jun 10, 2026

28Sep 18, 2026
Sep 18, 2026Nothing in our recordNo ALKS story, brief or results filing in our record that dayGroup −0.1% did not move with it
−0.1% did not move with itMRK −0.2 · JNJ −0.1 · LLY +0.0 · ABBV −0.0
−7.11%
27Aug 20, 2026
Aug 20, 2026Nothing in our recordNo ALKS story, brief or results filing in our record that dayGroup −2.2% moved the same way
−2.2% moved the same wayLLY −2.8 · JNJ −2.2 · MRK −2.1 · ABBV −1.6
−4.30%
26Jul 29, 2026
Jul 29, 2026Nothing in our recordNo ALKS story, brief or results filing in our record that dayGroup −0.7% did not move with it
−0.7% did not move with itMRK −1.1 · LLY −0.9 · JNJ −0.5 · ABBV +0.0
−4.28%
25Jul 28, 2026
Jul 28, 2026ResultsThe first close after a results filing (SEC 8-K, Item 2.02)Group +1.4% did not move with it
+1.4% did not move with itABBV +2.5 · LLY +1.9 · MRK +0.8 · JNJ +0.3
−4.23%
24Jul 2, 2026
Jul 2, 2026Nothing in our recordNo ALKS story, brief or results filing in our record that dayGroup +3.5% moved the same way
+3.5% moved the same wayABBV +4.0 · JNJ +3.6 · MRK +3.3 · LLY +1.9
+5.53%
23Jun 29, 2026
Jun 29, 2026Nothing in our recordNo ALKS story, brief or results filing in our record that dayGroup +1.0% did not move with it
+1.0% did not move with itLLY +1.8 · JNJ +1.5 · MRK +0.6 · ABBV +0.4
−4.63%
22Jun 26, 2026
Jun 26, 2026Nothing in our recordNo ALKS story, brief or results filing in our record that dayGroup +4.1% moved the same way
+4.1% moved the same wayLLY +7.1 · ABBV +4.2 · JNJ +4.0 · MRK +2.6
+4.26%
21Jun 25, 2026
Jun 25, 2026Nothing in our recordNo ALKS story, brief or results filing in our record that dayGroup +2.6% moved the same way
+2.6% moved the same wayMRK +4.0 · ABBV +3.5 · JNJ +1.6 · LLY +0.9
+4.72%
20Jun 24, 2026
Jun 24, 2026Nothing in our recordNo ALKS story, brief or results filing in our record that dayGroup +0.8% did not move with it
+0.8% did not move with itLLY +0.9 · MRK +0.8 · JNJ +0.8 · ABBV +0.1
+4.95%
19Jun 23, 2026
Jun 23, 2026Nothing in our recordNo ALKS story, brief or results filing in our record that dayGroup +2.7% moved the same way
+2.7% moved the same wayMRK +3.6 · JNJ +3.4 · ABBV +2.1 · LLY +0.5
+4.45%
18Jun 9, 2026
Jun 9, 2026Before our storiesGroup +0.6% did not move with it
+0.6% did not move with itJNJ +2.1 · ABBV +1.1 · LLY −0.4 · MRK +0.1
+4.33%
17May 29, 2026
May 29, 2026Before our storiesGroup −1.5% did not move with it
−1.5% did not move with itJNJ −2.4 · LLY −1.9 · MRK −1.0 · ABBV −0.4
+5.63%
16May 28, 2026
May 28, 2026Before our storiesGroup +0.7% did not move with it
+0.7% did not move with itLLY +4.0 · ABBV +1.5 · MRK −0.3 · JNJ −0.2
+4.86%
15May 12, 2026
May 12, 2026Before our storiesGroup +1.8% did not move with it
+1.8% did not move with itABBV +2.5 · LLY +2.4 · JNJ +1.3 · MRK +1.0
+7.95%
14May 5, 2026
May 5, 2026ResultsThe first close after a results filing (SEC 8-K, Item 2.02)Group +0.3% did not move with it
+0.3% did not move with itLLY +2.2 · ABBV −1.0 · JNJ +0.6 · MRK +0.0
+6.09%
13Apr 10, 2026
Apr 10, 2026Before our storiesGroup −1.4% did not move with it
−1.4% did not move with itABBV −2.1 · LLY −1.6 · JNJ −1.2 · MRK −1.0
−4.47%
12Apr 8, 2026
Apr 8, 2026Before our storiesGroup +2.5% did not move with it
+2.5% did not move with itMRK +3.3 · ABBV +2.5 · LLY +2.4 · JNJ +1.2
+5.30%
11Mar 31, 2026
Mar 31, 2026Before our storiesGroup +1.9% did not move with it
+1.9% did not move with itLLY +3.7 · ABBV +2.0 · MRK +1.9 · JNJ +0.8
+17.28%
10Mar 19, 2026
Mar 19, 2026Before our storiesGroup −0.2% did not move with it
−0.2% did not move with itABBV −1.0 · MRK −0.3 · JNJ +0.1 · LLY −0.1
+4.41%
9Feb 25, 2026
Feb 25, 2026ResultsThe first close after a results filing (SEC 8-K, Item 2.02)Group −0.9% did not move with it
−0.9% did not move with itLLY −1.3 · MRK −1.2 · ABBV −0.7 · JNJ −0.5
−7.04%
8Feb 12, 2026
Feb 12, 2026Before our storiesGroup +1.9% did not move with it
+1.9% did not move with itABBV +3.0 · LLY +2.3 · JNJ +1.5 · MRK −0.1
−4.64%
7Jan 21, 2026
Jan 21, 2026Before our storiesGroup +1.3% did not move with it
+1.3% did not move with itLLY +3.6 · MRK +1.5 · ABBV +1.0 · JNJ −0.1
+6.61%
6Jan 14, 2026
Jan 14, 2026Before our storiesGroup +1.4% did not move with it
+1.4% did not move with itMRK +2.5 · JNJ +2.3 · ABBV +0.5 · LLY −0.4
+5.04%
5Nov 14, 2025
Nov 14, 2025Before our storiesGroup +0.1% did not move with it
+0.1% did not move with itJNJ +0.3 · LLY +0.2 · ABBV +0.0 · MRK −0.0
−6.35%
4Nov 12, 2025
Nov 12, 2025Before our storiesGroup +1.8% did not move with it
+1.8% did not move with itABBV +3.6 · LLY +3.0 · MRK +0.6 · JNJ +0.3
−7.11%
3Oct 28, 2025
Oct 28, 2025ResultsThe first close after a results filing (SEC 8-K, Item 2.02)Group −0.9% did not move with it
−0.9% did not move with itJNJ −1.8 · MRK −1.1 · LLY −0.8 · ABBV −0.2
+4.31%
2Oct 16, 2025
Oct 16, 2025Before our storiesGroup +0.0% did not move with it
+0.0% did not move with itLLY −0.9 · JNJ +0.5 · ABBV +0.3 · MRK −0.2
−4.44%
1Sep 29, 2025
Sep 29, 2025Before our storiesGroup +0.7% did not move with it
+0.7% did not move with itABBV +1.2 · JNJ +1.1 · LLY +0.3 · MRK +0.0
+4.12%

A story on the same day is not a cause, and a group move is not proof either. Group: LLY, JNJ, ABBV, MRK, the largest companies in ALKS’s SEC industry; “the same way” means the same direction and at least half as far. Prior-session closes only; not a call, not advice.

The numbers · FY2025, filed

SEC EDGAR

Market cap$6.9B

Revenue$1.5B−5.20%

Net income$241.7M

EPS, diluted$1.43−34.10%

Operating margin17.2%

Return on equity13.3%

All filed figures

Snapshot

SEC EDGAR · FY 2025-12-31

SectorHealthcare

Market Cap$6.9B

Enterprise Value$5.7B

Income$241.7M

Sales$1.5B

Book/sh$10.84

Cash/sh$6.67

Dividend TTM—

Payout—

Employees—

IPO—

Quick Ratio3.19

Current Ratio3.55

Debt/Eq—

EPS (ttm)$1.43

EPS this Y-34.1%

EPS past 3/5Y—

Sales past 3/5Y9.9%

EPS Y/Y TTM-34.1%

Sales Y/Y TTM-5.2%

Shs Outstand167.76M

ROA9.7%

ROE13.3%

ROIC30.1%

Gross Margin—

Oper. Margin17.2%

Profit Margin16.4%

Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue by fiscal year

$1.2B

FY21

$1.1B

FY22

$1.7B

FY23

$1.6B

FY24

$1.5B

FY25

Operating leverage — margins

GrossOperatingNet

Financials, annual · income and cash flowSEC EDGAR · open ▸

Financials — annual

SEC EDGAR · last 5 FY · tap a row to explain it

USD	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$1.2B	$1.1B	$1.7B	$1.6B	$1.5B
Gross Profit	—	—	—	—	—
Operating Income	$97.7M	$-6.1M	$414.1M	$420.6M	$254.0M
Net Income	$-48.2M	$-158.3M	$355.8M	$367.1M	$241.7M
Diluted EPS	$-0.29	$-0.97	$2.10	$2.17	$1.43
Operating Cash Flow	$101.7M	$21.0M	$401.4M	$439.1M	$520.8M
Free Cash Flow	$73.7M	$-17.2M	$353.3M	$405.6M	$480.3M

Same industry

In the screener →

LLY$1.11T JNJ$653.6B ABBV$467.1B MRK$367.1B ABT$175.3B PFE$163.4B VRTX$133.4B BMY$128.4B

Follow the news. Track the move.

ALKS story timeline

Company updates and connected market context, with the dated price move attached.

Stories

Direct

Sector context/Earnings

Aug 24

Alkermes narcolepsy drug shows positive phase 2 trial results

Alkermes said its narcolepsy drug produced positive results in a Phase 2 trial, adding a potentially important development-stage asset to its portfolio. With no trial metrics or regulatory details disclosed here, the setup is constructive for the pipeline but not yet sufficient for a high-conviction earnings reset.

Since story

-17.0%

2026-08-25 → 2026-09-25

Investing.com · 34d ago

View both sides →

Follow the news. Track the move.